Home » Stocks » CERT

Certara, Inc. (CERT)

Stock Price: $29.73 USD 1.62 (5.76%)
Updated Apr 22, 2021 4:00 PM EDT - Market closed
Market Cap 3.96B
Revenue (ttm) 243.53M
Net Income (ttm) -49.40M
Shares Out 133.25M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE 126.58
Dividend n/a
Dividend Yield n/a
Trading Day April 22
Last Price $29.73
Previous Close $28.11
Change ($) 1.62
Change (%) 5.76%
Day's Open 28.15
Day's Range 28.05 - 30.55
Day's Volume 354,191
52-Week Range 24.58 - 41.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced that it will release preliminary financial results for the first quarter of 2021 after market close on May 6, 2021.

14 hours ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--Certara announced the closing of its underwritten public offering of its common stock at a public offering price of $25.00 per share.

3 weeks ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--Certara announced the pricing of its public offering of common stock by certain existing stockholders at a price of $25.00 per share.

4 weeks ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)-- #anonymization--TrialAssure® – a leading, global software company advancing clinical trial disclosure, data sharing, and transparency – has announced today that Certar...

1 month ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it is set to join the Russell 1000® Index.

1 month ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--Certara, a global leader in biosimulation, today reported its preliminary results for the fourth quarter and full year ending December 31, 2020.

1 month ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced that William Feehery, CEO and Andrew Schemick, CFO will virtually present at the Barclays Global Healthcare Conference.

1 month ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--2020 was the 7th consecutive year where 90% of new drug & biologic approvals by the FDA were received by Certara's customers.

1 month ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--Certara will release preliminary financial results for the fourth quarter and full year of 2020 after the market close on Thursday, March 4, 2021.

2 months ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)-- #Biologics--Certara, Inc. today announced the release of version 20 of its Simcyp™ Physiologically-based Pharmacokinetic (PBPK) Simulator platform.

2 months ago - Business Wire

STOCKHOLM, Dec. 17, 2020 /PRNewswire/ -- EQT is pleased to announce that on 10 December 2020, the EQT VII portfolio company Certara, Inc. ("Certara"), a global leader in biosimulation based on 2019 reve...

4 months ago - PRNewsWire

PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced that it closed its upsized initial public offering of 33,413,250 shares of common stock at $23.00 per share.

4 months ago - Business Wire

Hot initial public offerings aren't just for technology companies.

Other stocks mentioned: ABCL
4 months ago - The Motley Fool

Drug Software Firm Certara Expands IPO to Raise $668 Million

YouTube video

Dec.11 -- Certara Inc., a maker of drug-development software, upsized its initial public offering and priced it above the marketed range to raise $668 million, adding to the red-hot week for U.S. listin...

4 months ago - Bloomberg Markets and Finance

Certara CEO on strong IPO debut

YouTube video

CNBC's "Squawk Alley" team discusses Certara's IPO with CEO William Feehery.

4 months ago - CNBC Television

Four companies increased the size of their deals.

Other stocks mentioned: ABCL
4 months ago - Barrons

PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced the pricing of its upsized initial public offering of 29,055,000 shares of its common stock at $23.00 per share.

4 months ago - Business Wire

The list of upcoming IPOs is starting to perk up. Here's a look at some interesting deals, including a variety of tech operators.

Other stocks mentioned: ABNB, AI, DASH, PUBM
4 months ago - InvestorPlace

Certara has filed proposed terms for its $500 million U.S. IPO.

4 months ago - Seeking Alpha

Certara, which provides biosimulation software and services used for drug development, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.u00a0However, this is lik...

5 months ago - NASDAQ

Certara, Inc. has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC

About CERT

Certara accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. Biosimulation is a powerful technology used to conduct virtual trials using virtual patients to predict how drugs behave in different individuals. Biopharmaceutical companies use our proprietary biosimulation software throughout drug discovery and development to inform critical decisions that not only save significant time and money but also advance drug safety and efficacy, improving millions of lives e... [Read more...]

Industry
Biotechnology
IPO Date
Dec 11, 2020
CEO
William F. Feehery
Employees
846
Stock Exchange
NASDAQ
Ticker Symbol
CERT
Full Company Profile

Financial Performance

In 2020, Certara's revenue was $243.53 million, an increase of 16.79% compared to the previous year's $208.51 million. Losses were -$49.40 million, 453.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Certara stock is "Buy." The 12-month stock price forecast is 36.00, which is an increase of 21.09% from the latest price.

Price Target
$36.00
(21.09% upside)
Analyst Consensus: Buy